GLP-1 Receptor Agonist Market, By Drug Type (Exenatide, Liraglutide, Dulaglutide, Semaglutide, and others), Brand (Bydureon, Victoza, Trulicity, Ozempic, and Others), Route of Administration (Injectable, Oral Formulations), Application (Type 2 Diabetes, Obesity, and Others) and region (North America, Europe, Asia-Pacific, Middle East and Africa and South America).
The global GLP-1 Receptor Agonist Market size is projected to reach a CAGR of 13.3% from 2023-2030.
Glucagon-like peptide-1 (GLP-1) receptor agonists bind to GLP-1 receptors and activate them to stimulate physiological processes in the body. GLP-1 receptor agonists interact with GLP-1 receptors present in the pancreatic beta cells to stimulate insulin secretion. Thus, GLP-1 receptor agonists can be used for the treatment of diabetes. The benefits of using GLP-1 receptor agonists for the treatment of type-2 diabetes include inhibition of glucagon production from pancreatic alpha cells in case of high blood sugar levels. Glucagon is a hormone responsible for increasing the concentration of glucose in the blood by stimulating the liver to convert glycogen into glucose. Moreover, GLP-1 receptor agonists can promote the proliferation of pancreatic beta-cell and decrease their apoptosis or cell death. Also, GLP-1 receptor agonists slow down the emptying of gastric juices which leads to the slow release of nutrients from the food, thus it prevents the spiking of blood glucose levels. GLP-1 receptor agonists can also be used to treat several other conditions such as obesity, liver cirrhosis, cardiovascular disease, and others.
Major factors that are expected to boost the growth of the glucagon-like peptide 1 (GLP-1) agonists market in the forecast period are the overall influence of individual-level factors, such as the population's increasing median age and health factors, such as rising obesity and inactivity rates among people, has resulted in an increase in the diabetes population over time, rise in the hectic lifestyle and unbalanced food diet and the hereditary history of diabetes disorders which upsurges the danger of growing diabetes and growing number of middle-class households, rise in the per capita income and increasing expenditure are one of the main contributors of the market growth. In addition, the enhanced healthcare infrastructure, technological developments, and the accessibility of skilled medical professionals will further provide potential opportunities for the growth of the glucagon-like peptide 1 (GLP-1) agonists market in the coming years.
On the other hand, the two major factors restraining the growth of the market are adverse effects related to the use of GLP-1 receptor agonist drugs and product recalls by market players.
COVID-19 has positively affected the glucagon-like peptide 1 (GLP-1) agonists market. During the lockdowns and isolation during the pandemic complicated diabetes management and medication adherence. Glucagon-like peptide 1 (GLP-1) agonists market promises due to their anti-inflammatory and anti-obesogenic qualities, as well as pulmonary protection and a positive impact on gut microbiota composition. Taking everything into account, the glucagon-like peptide 1 (GLP-1) agonists market appears to be a promising option for the treatment of COVID-19-infected patients with or without type 2 diabetes, as well as excellent antidiabetic (glucose-lowering) medications during COVID-19 pandemics.
Within the pharmaceutical sector, the GLP-1 receptor agonist market is a fast-expanding and changing subsegment. This market is expanding as a result of rising rates of diabetes and obesity, improvements in medication research, and greater public awareness of the value of disease management. The market is now controlled by a small number of significant competitors, including Novo Nordisk and Eli Lilly, although there is room for disruption from more recent entries with novel oral formulations and drug delivery systems. The oral GLP-1 receptor agonist market is anticipated to develop at the quickest rate in the upcoming years as the market expands. The category for type 2 diabetes is anticipated to have the biggest market share, while the segment for obesity is anticipated to expand quickly as well. The largest and fastest-growing markets are predicted to be in North America and Asia-Pacific. Overall, the market for GLP-1 receptor agonists offers tremendous opportunities for pharmaceutical firms to create and distribute ground-breaking treatments for diabetes and obesity that will enhance the lives of millions of people worldwide.
North America to Dominate the Market